ECG
CYTH

EPIQ Capital Group’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

EPIQ Capital Group’s Portfolio CYTH Stock Details CYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$407K Sell
689,447
-49,979
-7% -$34.7K 0.11% 52
2024
Q3 		$583K Sell
739,426
-77,844
-10% -$77.8K 0.17% 42
2024
Q2 		$1.04M Sell
817,270
-36,545
-4% -$48.3K 0.37% 27
2024
Q1 		$1.19M Buy
+853,815
New +$1.41M 0.47% 22

Other funds holding CYTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FFVM
Founders Fund VI Management San Francisco, California $45.8K AUM 58.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

EPIQ Capital Group's CYTH Position: Q4 2024 in Review

EPIQ Capital Group reduced its Cyclo Therapeutics, Inc. Common Stock (CYTH) stake by 6.8% in Q4 2024, selling an estimated $34.7K and leaving 689,447 shares worth $407K. The position accounts for 0.11% of the portfolio, ranked #52.

EPIQ Capital Group first reported a position in CYTH in Q1 2024 and has held it in 4 quarters since. The position peaked at $1.19M in Q1 2024. 22 funds tracked by Wall St. Rank hold CYTH as of Q4 2024.

  • EPIQ Capital Group held 689,447 shares of Cyclo Therapeutics, Inc. Common Stock worth $407K as of Q4 2024.
  • EPIQ Capital Group sold 49,979 Cyclo Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $34.7K.
  • Cyclo Therapeutics, Inc. Common Stock made up 0.11% of EPIQ Capital Group's portfolio in Q4 2024, its #52 holding.
  • EPIQ Capital Group first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q1 2024 and has held it in 4 quarters since.
  • EPIQ Capital Group's Cyclo Therapeutics, Inc. Common Stock position peaked at $1.19M in Q1 2024.
  • 22 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q4 2024.

Based on EPIQ Capital Group's 13F filing for Q4 2024, filed 7 Feb 2025.